Development of formulations that enhance physical stability of viral vectors for gene therapy

Gene Therapy

Volumn 8, Issue 17, 2001, Pages 1281-1290

  Croyle, M A ^a   Cheng, X ^a   Wilson, J M ^b  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

AAV; Adenovirus; Formulation; Lyophilization; Physical stability

Indexed keywords

BETA GALACTOSIDASE; BUFFER; CARBOHYDRATE; CYCLODEXTRIN; MANNITOL; POTASSIUM DIHYDROGEN PHOSPHATE; SUCROSE; SURFACTANT; VIRUS VECTOR;

ADENO ASSOCIATED VIRUS; ADENOVIRUS; ANIMAL EXPERIMENT; ARTICLE; CELL PROTECTION; CLINICAL TRIAL; COMPLEX FORMATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG FORMULATION; DRUG STABILITY; DRUG SYNTHESIS; DRUG TISSUE LEVEL; ESCHERICHIA COLI; FREEZE DRYING; GENE THERAPY; HUMAN; MOUSE; MULTICENTER STUDY; NONHUMAN; PRIORITY JOURNAL; STORAGE; TEMPERATURE; VIRUS CONCENTRATION; VIRUS TITRATION;

ADENOVIRIDAE; DEPENDOVIRUS; GENE THERAPY; GENETIC ENGINEERING; GENETIC VECTORS; HUMANS; TRANSDUCTION, GENETIC;

ADENO-ASSOCIATED VIRUS; ADENOVIRIDAE; ANIMALIA; DNA VIRUSES; ESCHERICHIA COLI; NEGIBACTERIA;

EID: 0034823799     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301527     Document Type: Article

References (54)

1. Gene transfer: From concept to therapy
2. Gene therapy: Designer promoters for tumour targeting
3. Tissue specific promoters in targeting systemically delivered gene therapy
4. Regulated gene expression systems
5. Facilities for large-scale production of vectors under GMP conditions
6. PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo
7. 'Stealth' adenoviruses blunt cell mediated and humoral immune responses against the vector and allow for significant gene expression upon re-administration
8. Cationic lipid structure and formulation considerations for optimal gene transfection of the lung
9. Increasing epithelial junction permeability enhances gene transfer to airway epithelia in vivo
10. Use of protamine to augment adenovirus-mediated cancer gene therapy
11. Beta-cyclodextrins enhance adenoviral-mediated gene delivery to the intestine
12. Factors that influence stability of recombinant adenoviral preparations for human gene therapy
13. Instability, stabilization, and formulation of liquid protein pharmaceuticals
14. Salt precipitation during the freeze-concentration of phosphate buffer solutions
15. Factors influencing drug absorption and drug availability
16. The transfer of technology from the laboratory to the clinic: In process controls and final product testing
17. Freeze-drying of proteins, part II: Formulation selection
18. The effects of formulation variables on the stability of freeze-dried human growth hormone
19. 13C solid-state NMR
20. Formulation of proteins in vacuum-dried glasses. II. Process and storage stability in sugar-free amino acid systems
21. Protein stability in the amorphous carbohydrate matrix: Relevance to anhydrobiosis
22. The mechanism of cryoprotection of proteins by solutes
23. Are freezing and dehydration similar stress vectors? A comparison of modes of interaction of stabilizing solutes with biomolecules
24. An infrared spectroscopic study of the interactions of carbohydrates with dried proteins
25. The control of protein stability and association by weak interactions with water: How do solvents affect these processes?
26. Freeze-drying: From empericism to predictability
27. Freeze-drying: From empiricism to predictability: The significance of glass transitions
28. Evaluation of the physical stability of freeze-dried sucrose-containing formulations by differential scanning calorimetry
29. Measurement of glass transition temperatures of freeze-concentrated solutes by differential scanning calorimetry
30. The effective use of differential scanning calorimetry in the optimization of freeze-drying processes and formulations
31. Applications of DSC in the development of improved freeze-drying processes for labile biologicals
32. Freeze-drying of proteins. Part 1: Process design
33. Formulation and stability of freeze-dried proteins: Effects of moisture and oxygen on the stability of freeze-dried formulations of human growth hormone
34. Moisture content in proteins: Its effects and measurement
35. Effect of process conditions on recovery of protein activity after freezing and freeze-drying
36. Haemoglobin lyophilized with sucrose: The effect of residual moisture on storage
37. The temperature dependence of internal molecular motions hydrated and dry alpha-amylase: The role of hydration in water in the dynamical transition of proteins
38. Impact of moisture on thermally induced denaturation and decomposition of lyophilized bovine somatotropin
39. Stabilities of suspensions of influenza virus dried by sublimation of ice in vacuo to different contents of residual moisture and sealed under different gases
40. Protein structure and freeze-drying: The effects of residual moisture and gases
41. A new technique for the assay of infectivity of human adenovirus 5 DNA
42. Gene therapy vectors based on adeno-associated virus type 1
43. Recombinant adeno-associated virus for muscle-directed gene therapy
44. Freeze-thaw studies of a model protein, lactate dehydrogenase, in the presence of cryoprotectants
45. Measurement of final container residual moisture in freeze-dried biological products
46. Determination of residual moisture content in freeze-dried viral vaccines: Karl Fischer, gravimetric, and thermogravimetric methodologies
47. Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis
48. Development of a highly efficient purification process for recombinant adenoviral vectors for oral gene delivery